Prescription Required
Formulation: Tablet
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Tablet
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Afinitor (active ingredient: everolimus) is a prescription targeted therapy used to treat certain cancers and tumour-related conditions.
Unlike traditional chemotherapy, targeted therapy acts on specific signals that help abnormal cells grow and survive. Afinitor blocks a protein pathway called mTOR, which is involved in cell growth, division, metabolism, and blood-vessel formation.
Afinitor is used to treat adults with advanced renal cell carcinoma, also known as RCC. Renal cell carcinoma is the most common type of kidney cancer in adults.
Advanced kidney cancer may have grown into nearby tissues or spread to other parts of the body. This is known as metastatic cancer.
Afinitor may be prescribed when the cancer has continued to grow or has not responded adequately after treatment with sunitinib or sorafenib.
Kidney cancer cells may use the mTOR pathway to grow, divide, and develop a blood supply.
By blocking this pathway, Afinitor may:
Afinitor may help control advanced kidney cancer, but it is not considered a cure. Treatment may continue until the cancer progresses or the side effects become unacceptable.
Afinitor is also used to treat adults with progressive pancreatic neuroendocrine tumours, commonly called pNETs.
These tumours begin in the neuroendocrine cells of the pancreas. Neuroendocrine cells produce hormones and help control several body functions.
Pancreatic neuroendocrine tumours are different from the more common type of pancreatic cancer, known as pancreatic adenocarcinoma. They may grow and respond to treatment differently.
Progressive disease means that the tumour has continued to grow, spread, or become more active over time.
A healthcare provider may use imaging tests, blood tests, symptoms, and other assessments to determine whether a pancreatic neuroendocrine tumour is progressing.
Afinitor may be considered when the tumour cannot be fully removed with surgery or has spread beyond the pancreas.
An unresectable tumour cannot be completely removed through surgery.
This may happen because the tumour:
Afinitor may help slow tumour growth when surgery is not a suitable treatment option.
A locally advanced pancreatic neuroendocrine tumour has grown beyond its original location and into nearby tissues or structures.
Although it may not have spread to distant organs, it may no longer be possible to remove it completely through surgery.
Afinitor may be used to help control the disease and delay further progression.
A metastatic pancreatic neuroendocrine tumour has spread from the pancreas to another part of the body.
Common sites of spread may include the liver, lymph nodes, bones, or lungs.
Afinitor works throughout the body and may help slow the growth of cancer cells in both the original tumour and areas where the cancer has spread.
Afinitor belongs to a class of medications called mammalian target of rapamycin inhibitors, commonly known as mTOR inhibitors.
The mTOR protein acts as part of an internal signalling system that tells cells when to grow, divide, produce proteins, and use nutrients.
In some cancer cells, the mTOR pathway is unusually active. This encourages uncontrolled growth and may help tumours develop new blood vessels.
Afinitor attaches to a protein inside the cell and reduces mTOR activity. This interferes with several processes that cancer cells need to survive and multiply.
Tumours need oxygen and nutrients from the blood to continue growing. Some tumours release signals that encourage the formation of new blood vessels.
This process is called angiogenesis.
By blocking the mTOR pathway, Afinitor may reduce some of the signals involved in angiogenesis. This may limit the tumour’s blood supply and help slow its growth.
Afinitor is considered a targeted cancer treatment because it focuses on a specific pathway involved in cancer-cell activity.
However, healthy cells also use the mTOR pathway. This means Afinitor can still affect normal tissues and cause significant side effects.
Possible effects may involve the mouth, lungs, immune system, kidneys, liver, blood cells, blood sugar, and cholesterol levels. Regular medical monitoring is required during treatment.
A healthcare provider will determine whether Afinitor is appropriate based on factors such as:
Treatment may be adjusted, temporarily interrupted, or stopped if serious side effects develop.
Regular medical appointments and laboratory tests are needed while taking Afinitor.
A healthcare provider may monitor:
Imaging tests may also be performed to check whether the tumour is stable, shrinking, or continuing to grow.
Afinitor may be used alone or as part of a broader cancer treatment plan. Other treatments may include surgery, radiation therapy, hormone therapy, or other targeted medications.
Afinitor helps control certain cancers, but it does not permanently cure advanced disease. The main treatment goal is usually to slow cancer progression and maintain health and daily function for as long as possible.
Continue taking Afinitor exactly as directed. Do not change the dose or stop treatment without speaking with the cancer care team.
Take Afinitor exactly as prescribed by your healthcare provider. It is usually taken by mouth once daily.
Take each dose at approximately the same time every day. This helps maintain a steady amount of everolimus in your body.
Afinitor may be taken with or without food. However, take it consistently the same way each day. This means taking every dose either with food or without food.
Swallow Afinitor tablets whole with a glass of water.
Do not crush, chew, split, or break the tablets. Damaging the tablet may change how the medication is absorbed and could expose you or another person to the medicine.
Handle the tablets carefully. Wash your hands if you come into contact with a broken or crushed tablet.
For several cancers and tumour-related conditions, the usual adult dose is 10 mg once daily.
This dose may be used for:
The correct dose depends on the condition being treated, liver function, other medications, treatment response, and side effects.
For postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, the usual Afinitor dose is 10 mg once daily.
Afinitor is usually taken together with exemestane when previous treatment with letrozole or anastrozole is no longer controlling the cancer.
Treatment may continue until the cancer progresses or side effects become unacceptable.
For eligible adults with progressive neuroendocrine tumours of the pancreas, gastrointestinal tract, or lungs, the usual dose is 10 mg once daily.
Afinitor may be prescribed when the tumour:
Treatment is generally continued while it is controlling the disease and the side effects remain manageable.
For advanced renal cell carcinoma, the usual dose is 10 mg once daily.
Afinitor may be used when kidney cancer has continued to grow after treatment with medicines such as sunitinib or sorafenib.
Your cancer care team will use imaging, blood tests, symptoms, and other assessments to determine whether treatment is working.
For adults with renal angiomyolipoma associated with tuberous sclerosis complex, the usual dose is 10 mg once daily.
This treatment may be used when the tumour does not require immediate surgery but has a risk of growth or complications.
Afinitor tablets and Afinitor Disperz tablets for oral suspension are different dosage forms.
Do not combine the two forms to make up your total dose. Use only the form prescribed by your healthcare provider. Afinitor Disperz must be prepared as an oral suspension and should not be swallowed whole like a regular tablet.
Your healthcare provider may lower the dose, temporarily interrupt treatment, or permanently stop Afinitor if you develop serious side effects.
Dose adjustments may be required for:
Do not change your dose or stop treatment on your own.
The liver helps process everolimus. People with liver impairment may have higher medication levels in their blood.
A healthcare provider may prescribe a lower dose based on the severity of the liver condition. Liver function may be checked before and during treatment.
Tell your healthcare provider if you develop yellow skin or eyes, dark urine, severe nausea, unusual tiredness, or pain in the upper-right side of the abdomen.
Some medications can change the amount of everolimus in the body. This may make Afinitor less effective or increase the risk of side effects.
Tell your healthcare provider about all prescription medicines, nonprescription products, vitamins, supplements, and herbal products you use.
Important interactions may occur with certain:
Your Afinitor dose or the interacting medication may need to be adjusted.
Avoid grapefruit, grapefruit juice, and other grapefruit-containing products during treatment unless your healthcare provider says they are safe.
Grapefruit can interfere with the way the body breaks down everolimus. This may raise medication levels and increase the risk of side effects.
Take the missed dose if you remember within six hours of your usual dosing time.
If more than six hours have passed, skip the missed dose for that day. Take your next dose at the regular time on the following day.
Do not take two doses at the same time or take extra tablets to replace a missed dose.
If you vomit after taking Afinitor, do not automatically take another dose.
Wait until your next scheduled dose unless your healthcare provider gives you different instructions. Taking an additional tablet could result in too much medication.
Taking too much Afinitor may increase the risk of serious side effects.
Contact your healthcare provider or go to the nearest emergency department immediately if you take more than prescribed. Bring the medication package with you when possible.
Afinitor can affect several parts of the body, so regular medical monitoring is important.
Your healthcare provider may check:
Blood tests may be needed before treatment begins and at regular intervals during therapy.
Afinitor is generally continued until the condition progresses, the medication stops providing enough benefit, or side effects become unacceptable.
The length of treatment varies from person to person. Some patients may use Afinitor for several months or longer.
Continue taking it every day unless your cancer care team tells you to pause or stop treatment.
Take Afinitor at the same time each day and consistently either with food or without food.
Do not crush, chew, split, or change the dose. Attend all laboratory tests and medical appointments so your healthcare provider can monitor your response and manage side effects promptly.
Afinitor (Everolimus) is available in the following forms and strength:
Afinitor may harm an unborn baby. Tell your healthcare provider if you are pregnant, planning to become pregnant, or think you may be pregnant.
Everolimus may also affect fertility in both men and women. These effects may be temporary or permanent. Speak with your healthcare provider about fertility preservation before starting treatment if you may want children in the future.
Use effective birth control during treatment and for the period recommended by your healthcare provider after the final dose.
Afinitor may cause or worsen high blood pressure.
Your healthcare provider may check your blood pressure before and during treatment. Contact them if you develop severe headaches, dizziness, blurred vision, chest discomfort, or unusually high blood pressure readings.
Afinitor may affect kidney function. Possible problems include increased protein in the urine, reduced kidney function, or, rarely, kidney failure.
Your healthcare provider may monitor kidney function with blood and urine tests.
Contact your healthcare provider if you experience:
Afinitor may cause noninfectious pneumonitis, which is inflammation of the lungs that is not caused by an infection. This condition can sometimes become serious.
Contact your healthcare provider promptly if you develop:
Seek immediate medical care if breathing becomes severe or suddenly worsens.
Mouth sores are a common side effect of Afinitor. They may appear as pain, redness, swelling, ulcers, or irritation inside the mouth.
Mouth sores often develop early in treatment. Your healthcare provider may recommend a steroid mouthwash to help prevent or manage them.
Avoid alcohol-containing mouthwashes, hydrogen peroxide, iodine, and other products that may irritate the mouth. Contact your healthcare provider if sores become painful, interfere with eating or drinking, or show signs of infection.
Afinitor weakens parts of the immune system and can increase the risk of bacterial, viral, fungal, or other infections. Existing infections may also become active again.
Possible signs of infection include:
Contact your healthcare provider promptly if you develop signs of an infection. Severe infections may require Afinitor to be paused or stopped.
Afinitor may increase blood sugar levels. The risk may be higher in people with diabetes or prediabetes.
Your healthcare provider may check your blood sugar before and during treatment. Diabetes medications may need to be adjusted.
Contact your healthcare provider if you develop increased thirst, frequent urination, unusual hunger, blurred vision, or severe tiredness.
Afinitor may cause tiredness, weakness, dizziness, or reduced alertness.
Avoid driving, operating machinery, or performing activities that require concentration until you know how the medication affects you.
Vision problems are not among the most common effects of Afinitor, but changes in vision may occur because of treatment-related complications or other medical conditions.
Contact your healthcare provider if you develop blurred vision, sudden vision loss, eye pain, or difficulty seeing clearly.
The liver helps process everolimus. People with liver impairment may have higher levels of the medication in their blood and may require a lower dose.
Tell your healthcare provider if you have liver disease. Liver function may be checked before and during treatment.
Seek medical advice if you develop yellowing of the skin or eyes, dark urine, severe nausea, unusual tiredness, or pain in the upper-right side of the abdomen.
Everolimus suppresses parts of the immune system. Increased risks of lymphoma and skin cancer are mainly associated with long-term immune-suppressing use, such as after an organ transplant.
Afinitor used for cancer treatment is given in a different clinical setting. Your healthcare provider will monitor you for unusual lumps, persistent swollen lymph nodes, or new or changing skin lesions during treatment.
The usual adult dose of Afinitor for several conditions is 10 mg once daily. However, the correct dose depends on the condition being treated, liver function, other medications, treatment response, and side effects. Your healthcare provider may lower the dose, pause treatment, or stop the medication if needed. Take Afinitor exactly as prescribed. Do not change your dose without speaking with your healthcare provider.
Take the missed dose if you remember within six hours of your usual dosing time. If more than six hours have passed, skip the missed dose and take your next dose at the regular time. Do not take two doses at once or take extra tablets to make up for a missed dose.
Afinitor may interact with certain medications, vitamins, supplements, and herbal products. These interactions may change how Afinitor works or increase the risk of side effects. Tell your healthcare provider about everything you take, including prescription medications, over-the-counter products, vitamins, and herbal supplements. Do not start, stop, or change another medication without speaking with your healthcare provider.
The time it takes for Afinitor to work varies from person to person. It also depends on the condition being treated and how the body responds to treatment. You may not notice an immediate improvement. Blood tests, imaging scans, symptoms, and other medical assessments are usually used to determine whether the treatment is working. Continue taking Afinitor for as long as directed. Do not stop treatment because you do not notice a quick change.
| Generic name: | Everolimus |
|---|---|
| Formulation: | Tablet |
| Strength(s): | 2.5mg, 5mg, 10mg |
| Quantities Available: | 30 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Afinitor (everolimus) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is standard for prescription medications to ensure continuous management of conditions like cancer without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Afinitor is available in different strengths, typically in 2.5 mg, 5 mg, and 10 mg tablets. The specific dosage prescribed by your healthcare provider will determine the quantity needed for a 90-day supply.
For example, if prescribed 10 mg daily, for a 90-day supply, you would order 90 tablets (90 days x 1 tablet per day).
No, we do not sell everolimus directly on our website. However, you can still purchase Afinitor, which contains everolimus as an active ingredient, from us. You can enjoy low prices on Afinitor when ordering through our platform. Please note that you will need a valid prescription from your healthcare provider to dispense the medication. You can submit your prescription by mailing it, faxing it, or uploading it securely through your online account.
Yes, we ship Afinitor (everolimus) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Afinitor (Everolimus). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Afinitor (Everolimus).
REVIEWS